Sarepta’s Muscle-Wasting Disease Drug Sidelined by Competitor’s Trial Failure

Drug Industry Daily
A A
The FDA has delayed Sarepta Therapeutics’ NDA submission for its Duchenne muscular dystrophy (DMD) drug because of a failure in trials of a similar drug.

To View This Article:

Login

Subscribe To Drug Industry Daily